180-Day Exclusivity Ruling On Cosopt Signals Need For Strong Patent Challenges
Executive Summary
FDA's decision that Hi-Tech forfeited its generic exclusivity for Merck's ophthalmic Cosopt (dorzolamide/timolol) means that firms may need to give more weight to the strength of their patent challenges as they make filing decisions in the future
You may also be interested in...
FDA Nixes Innovator Industry-Backed Changes To Citizen Petition Rule
Agency rejects PhRMA requests to ease certification process and limit rule's application; separately, law firm Hyman, Phelps & McNamara objects to FDA practice of delaying ANDA approval announcements until it issues a petition decision.
Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics
FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar
Teva May Have To Forfeit Exclusivity For Hyzaar/Cozaar Generics
FDA's recent wave of decisions outlining when generic firms forfeit their 180-day exclusivity appears destined to wipe out one of Teva's most prized possessions: exclusivity for Merck's Hyzaar and Cozaar